Research finds drug prices increased without adding new clinical benefits
The net prices of five drugs included in a new study from the Institute for Clinical and Economic Review increased without clinical justification in 2023. These increases led to $815 million incremental added costs for U.S. payers.
Related News Articles
Headline
The 4th U.S. Circuit Court of AppealsMay 28 agreed to rehear challenges to 340B contract pharmacy laws from West Virginia and Maryland. In April, a three-judge…
Headline
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 editorial criticizing the 340B Drug…
Headline
The White House May 18 announced an expansion of TrumpRx.gov, which now features more than 600 generic drugs. The direct-to-consumer platform serves as a hub…
Headline
The New York Times published a letter to the editor May 16 by AHA President and CEO Rick Pollack that responds to a May 4 op-ed that claimed hospitals are…
Headline
The AHA today urged Eli Lilly to abandon its 340B Drug Pricing Program claims-data policy and work with the AHA to develop a functional third-party…
Headline
An AHA blog says an essay published in The New York Times wrongly frames hospitals as the leading “culprit” behind rising health care costs. “It…